| Literature DB >> 35047799 |
Jiajie Yu1, Fei Shan2, Allison Hirst3, Peter McCulloch3, Youping Li1, Xin Sun1.
Abstract
INTRODUCTION: Approximately £1130 billion was invested in research worldwide in 2016, and 9.6% of this was on biomedical research. However, about 85% of biomedical research investment is wasted. The Lancet published a series to identify five categories relating to research waste and in 2014. Some categories of research waste in surgery are avoidable by complying with the Idea, Development, Exploration, Assessment, Long-term follow-up (IDEAL) framework for it enables researchers to design, conduct and report surgical studies robustly and transparently. This review aims to examine the extent to which surgical studies adhered to the IDEAL framework and estimate the amount of overall research waste that could be avoided if compliance was improved.Entities:
Keywords: devices; health technology; methodology
Year: 2021 PMID: 35047799 PMCID: PMC8647616 DOI: 10.1136/bmjsit-2020-000050
Source DB: PubMed Journal: BMJ Surg Interv Health Technol ISSN: 2631-4940
Figure 1Flow chart for screening and data extraction. IDEAL, Idea, Development, Exploration, Assessment, Long term.
IDEAL Compliance Appraisal tool
| Stage | Domains | Option |
| Stage 1 | Idea | |
| Item 1 | Was the patient selection process fully described. | □Yes □Partial Yes □No |
| Item 2 | Did the study fully describe the procedure of interest. | □Yes □Partial Yes □No |
| Item 3 | Did the study clearly state the rationale for the innovation. | □Yes □Partial Yes □No |
| Item 4 | Did the study appropriately report relevant outcome measures. | □Yes □Partial Yes □No |
| Stage 2a | Development | |
| Item 1 | Did the study fully describe the patient selection process as used in the first case in the 2a study. | □Yes □Partial Yes □No |
| Item 2 | Did the study describe the procedure of interest as it was performed in the first case in the 2a study. | □Yes □Partial Yes □No |
| Item 3 | Did the study report all changes in the design, use of the device or the way of performing the procedure. | □Yes □Partial Yes □No |
| Item 4 | Did the study report key outcome measures sequentially (case by case) to allow evaluation of change. | □Yes □No |
| Item 5 | Did the study state if the innovation stable enough to move to stage 2b. | □Yes □Partial Yes □No |
| Stage 2b | Assessment | |
| Item 1 | Was there a unified description of the intervention and accepted variation. | □Yes □Partial Yes □No |
| Item 2 | Did the study define the measures used to evaluate the quality of the procedure or device use. | □Yes □No |
| Item 3 | Did the study provide information about the learning curve assessment. | □Yes □Partial Yes □No |
| Item 4 | Did the study provide a qualitative evaluation of the stakeholder values. | □Yes □Partial Yes □No |
| Item 5 | Did the study describe a pre-planned review of results and discussion to achieve the agreement on the stage 3 trial. | □Yes □Partial Yes □No |
| Item 6 | Did the study report the use of the primary outcome effect estimate to perform power calculations for possible RCTs. | □Yes □No |
| Stage 4 | Long-term follow-up. | |
| Item 1 | Did the study describe the data source. | □Yes □No |
| Item 2 | Did the study clearly and precisely describe the definition of the dataset. | □Yes □Partial Yes □No |
| Item 3 | Did the study conduct appropriate analysis of data. | □Yes □Partial Yes □No |
| Item 4 | Did the study report the missing data of the dataset. | □Yes □Partial Yes □No |
RCT, randomised controlled trial.